

February 24, 1966

Dr. Joseph G. Bird
Director, Division of Clinical Research
Sterling-Winthrop Research Institute
A Division of Sterling Drug Inc.
Rensselaer, New York 12144

Dear Dr. Bird:

I am pleased to enclose the Statement of Investigator Form FD-1572 regarding the study of the EEG effects of cyclazocine. I have read the two brochures which you have submitted and your letter with great interest.

The reaction of hypersynchrony which is described in the section related to cats would permit the classification of this compound as a narcotic or sedative. The behavioral observations, however, indicating a 5% development of hallucinations would suggest that some subjects do develop a desynchronized pattern at the dosages given.

We would like to take advantage of the opportunities presented by these laboratories to determine the EEG spectrum of activity in some of the psychotic subjects and possibly a number of volunteers.

Since our dosages will probably be less than 1 mg, we would appreciate a supply of ampules of 1 mg and .5 mg potency. A dozen ampules of each would be an adequate supply.

We would be delighted to have you visit us in St. Louis on one of your trips. Perhaps we should establish a dosage schedule which demonstrates some of the behavioral and EEG effects of cyclazocine and then send this information to you. I would agree that at that time, a visit might be mutually helpful.

Thank you for your assistance.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp